Abciximab readministration: A single-operator community-hospital experience

Area of Science:

• Cardiology
• Pharmacology

Background:

• Abciximab, a monoclonal antibody targeting platelet glycoprotein IIb/IIIa receptors, is established for reducing ischemic complications in coronary interventions.
• The safety and efficacy of repeat abciximab administration at separate intervals require further investigation.

Purpose of the Study:

• To evaluate the efficacy and safety of readministering abciximab in patients who have previously received the drug.
• To assess for recurrent ischemia, bleeding complications, and thrombocytopenia following a second dose of abciximab.

Main Methods:

• Retrospective chart review of 35 patients receiving two doses of abciximab at distinct times.
• Clinical monitoring for ischemic events and bleeding complications.
• Measurement of hemoglobin and platelet counts pre- and post-readministration.

Main Results:

• No cardiac-related deaths, myocardial infarctions, or recurrent ischemic events were observed.
• No significant bleeding complications occurred; one patient had a hemoglobin drop >3 gm/dl.
• One instance of severe, uncomplicated thrombocytopenia resolved without transfusion; no profound thrombocytopenia was noted.

Conclusions:

• Readministration of abciximab appears well-tolerated in patients undergoing coronary interventions.
• Repeat dosing of abciximab did not demonstrate altered efficacy or safety profiles.
• Abciximab can be safely readministered without compromising patient outcomes.